| Literature DB >> 28509134 |
Mercedes Cao1, Tamara Ferreiro2, Bruna N Leite2, Francisco Pita2, Luis Bolaños2, Francisco Valdés2, Angel Alonso2, Eduardo Vázquez3, Juan Mosquera3, María Trigás4, Santiago Rodríguez5.
Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by hemolysis, thrombocytopenia, and renal failure. It is related to genetic mutations of the alternative complement pathway and is difficult to differentiate from other prothrombotic microangiopathies. Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg-Strauss syndrome, CSS) is a systemic ANCA-associated vasculitis and a hypereosinophilic disorder where eosinophils seem to induce cell apoptosis and necrosis and therefore, vasculitis. Here, we report the case of two CSS patients with a genetic complement disorder consistent with aHUS diagnosis. Both patients showed histologic features that supported the diagnosis of CSS, and a genetic complement study confirmed the suspected aHUS diagnosis. In the case where eculizumab was administered, the global response was excellent. There is very limited understanding of the genetics and epidemiology of both, atypical HUS and EGPA, but considering our two patients we suggest that an etiopathogenic link exists among patients diagnosed with both entities.Entities:
Keywords: ANCA; Churg–Strauss syndrome; Complement; EGPA; Eculizumab; Eosinophilia; TMA; Vasculitis; aHUS
Year: 2017 PMID: 28509134 PMCID: PMC5438815 DOI: 10.1007/s13730-017-0251-8
Source DB: PubMed Journal: CEN Case Rep ISSN: 2192-4449